16
Participants
Start Date
September 1, 2022
Primary Completion Date
October 23, 2023
Study Completion Date
October 30, 2024
Semaglutide Pen Injector
semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention
Diabetes and Endocrinology Research Center, Buffalo
National Center for Advancing Translational Sciences (NCATS)
NIH
State University of New York at Buffalo
OTHER